Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.

Sana Biotechnology’s investigational allogeneic islet cell therapy has survived and secreted insulin for more than one year ...

Pluri (PLUR), an established global leader in the development and manufacturing of cell-based therapeutics, launches new revenue-generating Contract Development and Manufacturing Organization (CDMO) ...

SHANGHAI, March 19 (Reuters) - AstraZeneca said on Thursday it will build a cell therapy manufacturing and supply base and an ...

Following through with its sizable investment commitment in China, AstraZeneca on Thursday unveiled plans to build a ...

With iPSCs continuing to emerge as an important source of starting materials for cell therapy developers, it is crucial to tackle key remaining challenges relating to cell culture scalability and ...

When Ron Cohen, M.D., CEO of Oryon Cell Therapies, recently dug into the company’s Parkinson’s disease data, he told Fierce ...

The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in ...

TOKYO--(BUSINESS WIRE)-- AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.’s Yokohama Technical ...

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene ...

The MarketWatch News Department was not involved in the creation of this content. Introducing cell therapy--grade cryopreservation and hypothermic storage solutions designed for consistency, quality, ...